Acadian Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-135,324
| Closed | -$249K | – | 1970 |
|
|
2023
Q1 | $249K | Sell |
135,324
-962,504
| -88% | -$1.19M | ﹤0.01% | 1212 |
|
|
2022
Q4 | $1.22M | Buy |
1,097,828
+298,443
| +37% | +$425K | 0.01% | 800 |
|
|
2022
Q3 | $1.87M | Sell |
799,385
-21,942
| -3% | -$77.7K | 0.01% | 657 |
|
|
2022
Q2 | $2.49M | Buy |
821,327
+2,974
| +0.4% | +$14.5K | 0.01% | 574 |
|
|
2022
Q1 | $5.55M | Sell |
818,353
-76,871
| -9% | -$548K | 0.02% | 444 |
|
|
2021
Q4 | $7.47M | Buy |
895,224
+6,859
| +0.8% | +$56.5K | 0.03% | 360 |
|
|
2021
Q3 | $6.6M | Buy |
888,365
+184,446
| +26% | +$1.14M | 0.03% | 394 |
|
|
2021
Q2 | $4.79M | Buy |
703,919
+218,774
| +45% | +$1.82M | 0.02% | 477 |
|
|
2021
Q1 | $4.98M | Sell |
485,145
-67,483
| -12% | -$739K | 0.02% | 478 |
|
|
2020
Q4 | $3.87M | Sell |
552,628
-302,494
| -35% | -$2.35M | 0.02% | 576 |
|
|
2020
Q3 | $6.98M | Sell |
855,122
-114,562
| -12% | -$710K | 0.03% | 375 |
|
|
2020
Q2 | $6.69M | Buy |
969,684
+11,267
| +1% | +$60.8K | 0.03% | 417 |
|
|
2020
Q1 | $4.55M | Buy |
958,417
+278,939
| +41% | +$1.61M | 0.03% | 414 |
|
|
2019
Q4 | $5.93M | Buy |
679,478
+259,817
| +62% | +$1.4M | 0.03% | 402 |
|
|
2019
Q3 | $1.4M | Buy |
419,661
+43,571
| +12% | +$174K | 0.01% | 795 |
|
|
2019
Q2 | $1.86M | Buy |
376,090
+84,557
| +29% | +$449K | 0.01% | 644 |
|
|
2019
Q1 | $1.81M | Buy |
291,533
+151,576
| +108% | +$732K | 0.01% | 715 |
|
|
2018
Q4 | $471K | Buy |
139,957
+79,266
| +131% | +$370K | ﹤0.01% | 917 |
|
|
2018
Q3 | $395K | Buy |
60,691
+38,086
| +168% | +$283K | ﹤0.01% | 932 |
|
|
2018
Q2 | $173K | Sell |
22,605
-64,297
| -74% | -$927K | ﹤0.01% | 1123 |
|
|
2018
Q1 | $1.94M | Sell |
86,902
-157,054
| -64% | -$3.49M | 0.01% | 593 |
|
|
2017
Q4 | $3.11M | Sell |
243,956
-73,291
| -23% | -$1.08M | 0.01% | 463 |
|
|
2017
Q3 | $4.94M | Buy |
317,247
+149,048
| +89% | +$2.11M | 0.02% | 371 |
|
|
2017
Q2 | $2.36M | Buy |
+168,199
| New | +$3.6M | 0.01% | 542 |
|
Other funds holding JNCE
Acadian Asset Management's JNCE Position: Q2 2023 in Review
Acadian Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 135,324 shares — an estimated $249K sold.
Acadian Asset Management first reported a position in JNCE in Q2 2017 and held it in 24 quarters. The position peaked at $7.47M in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Acadian Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Acadian Asset Management sold 135,324 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $249K.
- Acadian Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 24 quarters.
- Acadian Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $7.47M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.